Improving Dementia Policy Through Evidence-Based Economic Research
Robert J. Brent examines which dementia interventions provide benefits that justify their costs. Using large-scale NACC data, his research gives healthcare professionals, economists, and policymakers a clearer basis for deciding where public resources can make the greatest difference.
- About The Author
robert j. brent
Robert J. Brent is Professor of Economics Emeritus at Fordham University in New York. His work focuses on cost-benefit analysis and its use in understanding difficult questions in healthcare and public policy.
Much of his recent research examines dementia interventions through an economic lens. Using large-scale NACC data, he studies whether medical and non-medical interventions produce benefits that justify their costs.
Through his books and published research, Brent aims to give researchers, healthcare professionals, economists, and policymakers clearer evidence for deciding which interventions deserve attention and public resources.
- About The Book
About The Book
Robert J. Brent’s books examine dementia interventions through an economic lens, asking not only what works, but what is worth supporting with public funds.
Cost-Benefit Analysis and Dementia
NEW INTERVENTIONS
This first volume looks beyond medicine to examine practical interventions that may help people living with dementia. Robert J. Brent applies cost-benefit analysis to areas such as education, Medicare eligibility, hearing aids, vision correction, and alternatives to nursing-home care, considering how each intervention affects dementia symptoms and everyday functioning.
The book goes further than simply asking whether an intervention is effective. It also considers the economic value of the results, comparing benefits with costs to determine whether an intervention is socially worthwhile. This gives policymakers and healthcare decision-makers a more practical way to think about where limited public resources can be used most effectively.
Cost-Benefit Analysis and Dementia
Medicine Interventions
In Cost-Benefit Analysis and Dementia: Medicine Interventions, economist Robert J. Brent examines the economic and social value of commonly used medical interventions for people living with dementia. Drawing on data from the National Alzheimer’s Coordinating Center (NACC), the book applies cost-benefit analysis to five categories of medicines: FDA-approved dementia medications, beta-blockers, antipsychotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and statins.
Moving beyond clinical effectiveness alone, Brent evaluates how these interventions affect dementia symptoms, mortality, life expectancy, and overall social welfare. The analysis offers a comparative perspective on which treatments may provide meaningful benefits relative to their costs and raises important questions about how limited healthcare resources should be allocated.
- the shelf
Explore Robert J. Brent’s Published Works
Cost-Benefit Analysis and Dementia: New Interventions
This ground-breaking book expertly brings together the many effective dementia interventions
Cost-Benefit Analysis and Dementia: MEDICINE INTERVENTIONS
In Cost-Benefit Analysis and Dementia: Medicine Interventions, economist Robert J. Brent
Setting Priorities for HIV/AIDS Interventions:
HIV/AIDS is much too complex a phenomenon to be understood only by reference to common sense
Advanced Introduction to Cost–Benefit Analysis
Elgar Advanced Introductions are stimulating and thoughtful introductions to major fields in the socia
Applied Cost–Benefit Analysis, Second Edition
This fully updated new edition continues in the vein of its predecessor by viewing cost-benefit analysis as applied
Cost-Benefit Analysis and Health Care Evaluations,
This fully updated new edition continues in the vein of its predecessor by viewing cost-benefit analysis as applied
Cost–Benefit Analysis for Developing Countries
Cost-benefit analysis is a key component in the evaluation of economic development strategies.
Handbook of Research on Cost–Benefit Analysis
This Handbook provides an authoritative overview of current research in the field of cost-benefit
- Research & Publications
Research & Publications
Browse Robert J. Brent’s books and research on cost-benefit analysis, dementia interventions, healthcare policy, and the use of economic evidence in public decision-making.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- BOOKS
cost-benefit analysis and dementia
2025
Lorem ipsum dolor sit amet, consectetur
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
- blogs and news
Dementia Research, Economics and Public Policy

We Ranked Every Dementia Treatment by What It’s Actually Worth. Here’s Who Won
After running a full economic evaluation on five widely used medications and comparing them against seven non-drug interventions, Robert J.

The Cheapest Pill in Your Medicine Cabinet Might Be the Best Dementia Treatment Around
Three medications into Robert J. Brent’s economic analysis of dementia treatments, the pattern wasn’t looking good. FDA-approved Alzheimer’s drugs: net

The Medication the FDA Already Warned Against, and Nursing Homes Still Use
Of every medication examined in Robert J. Brent’s new economic analysis of dementia treatments, one stands out as the most
- testimonials
What Readers Are Saying
“I was a little worried this would be too technical for me, especially with the economics side of it. It wasn’t. The explanations are clear, and I came away understanding dementia interventions and the decisions around them much better than I did before.”
“The part I found most interesting was the way the book looks at cost alongside results. We hear a lot about whether a treatment works, but not always whether the benefit is worth what is being spent on it. That gave me a different way of looking at healthcare decisions.”
“There is a lot of research in this book, but Robert J. Brent does a good job of explaining what the numbers actually mean. I never felt like I was just reading statistics for the sake of statistics. There was always a reason behind them.”
“I liked that the book wasn’t trying to make dramatic claims. It looks at the evidence, explains what was found, and lets the results speak for themselves. For a subject as complicated as dementia, I appreciated that approach.”
“This book made me think about dementia research from a side I hadn’t really considered before. The medical questions are important, of course, but so are the economic ones. Bringing the two together made the discussion much more useful for me.”
- contact us
